Congenital hypogonadotrophic hypogonadism (CHH) is a rare form of infertility caused by deficient secretion or action of gonadotrophin-releasing hormone.
There is no consensus regarding the optimal approach to fertility treatment in CHH men. In most cases, appropriate hormonal treatment with human chorionic gonadotrophin with or without follicle stimulating hormone will induce testicular development, spermatogenesis and fertility. Recent studies have examined sequential treatment with FSH pre-treatment to optimize fertility outcomes in severely affected CHH patients. This paper reviews historical and recent literature to summarize the current evidence on therapeutic approaches for CHH men seeking fertility.
Written by:
Dwyer AA, Raivio T, Pitteloud N. Are you the author?
Endocrinology, Diabetes and Metabolism Service of the Centre Hospitalier Universitaire Vaudois (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland; Institute of Biomedicine/Physiology, University of Helsinki, Helsinki, Finland; The Children's Hospital, Helsinki University Central Hospital (HUCH), Helsinki, Finland; University of Lausanne, Faculty of Biology & Medicine, Institute of Physiology and the Endocrinology, Diabetes and Metabolism Service of the Centre Hospitalier Universitaire Vaudois, Rue du Bugnon 46, 1011 Lausanne, Switzerland. ; ;
Reference: Best Pract Res Clin Endocrinol Metab. 2015 Jan;29(1):91-103.
doi: 10.1016/j.beem.2014.10.005
PubMed Abstract
PMID: 25617175